Results 111 to 120 of about 5,401 (225)
Calcineurin Inhibitors in Atopic Dermatitis: Balancing Tradition with Emerging Therapeutics
Atopic dermatitis (AD) is a common chronic inflammatory condition of the skin that has increased dramatically over the past decade and significantly impacts individual quality of life.
Rakesh Kumar +4 more
doaj +1 more source
The permeabilities of normal human and normal, inflamed, or corticosteroid (CS) pretreated skin of young domestic pigs for pimecrolimus and tacrolimus were compared in vitro, using Franz-type diffusion cells.
Josef G. Meingassner +7 more
core +1 more source
Background. Modern therapy of patients with atopic dermatitis involves the long-term use of topical medications that can affect different stages of the disease pathogenesis.
O. V. Kirichenko +3 more
doaj +1 more source
PIMECROLIMUS IN THE TREATMENT OF ATOPIC ECZEMA IN CHILDREN
In the article, the authors discuss the local treatment of atopic eczema. They give data from the series of clinical studies on the application of non steroid medication in the children — calcineurin blocker pimecrolimus.
K.E. Efendieva, Yu.G. Levina
doaj +2 more sources
Pimecrolimus Induces Apoptosis of Mast Cells in a Murine Model of Cutaneous Mastocytosis
<i>Background:</i> Cutaneous mastocytosis (CM) is a common type of mastocytosis. Current treatment of CM is generally symptomatic. Pimecrolimus has been demonstrated as an effective anti-inflammatory drug for the treatment of inflammatory ...
Zhongcai Ma +3 more
core +1 more source
Topical pimecrolimus in the treatment of genital lichen Sclerosu
Pimecrolimus is a drug belonging to the class of macrolactamic immunosuppressants, similar to tacrolimus, and has been employed mainly in the treatment of atopic dermatitis, but is also active in other skin diseases, including genital lichen sclerosus ...
Andreassi M., Bilenchi R.
core +1 more source
The absorption and disposition of pimecrolimus, a calcineurin inhibitor developed for the treatment of inflammatory skin diseases, was investigated in four healthy volunteers after a single oral dose of 15 mg of [(3)H]pimecrolimus.
Glaenzel, Ulrike +10 more
core
Pimecrolimus induced tinea incognito masquerading as intertriginous psoriasis
A 58-year-old, obese, male, army officer was presented with tinea incognito of the groin masking intertriginous psoriasis. According to his history, he had pruritic, symmetrical erythematous eruption of the groin of 2-month duration that he treated ...
Koumantaki-Mathioudaki, E., Rallis, E.
core +1 more source

